Our Time Line
The Cosette Pharmaceuticals Story
October 2026
Industry Leadership
October 2026 - Cosette Pharmaceuticals Announces FDA Approval of EVOXAC ® (cevimeline HCl) Oral Solution, Marking Cosette’s First New Drug Application (NDA) Approval
April 2026
April 2026 - Cosette Pharmaceuticals Expands Branded Portfolio through Acquisition of SYMPAZAN® and Additional Products from Assertio
January 2026
January 2026 - Expanded Infrastructure: Officially opened the new, expanded corporate headquarters in Bridgewater, NJ, supporting a workforce that has grown to 350+ employees.
December 2025
December 2025 - First-to-Market Launch: FDA approval and launch of the first generic CIPRO® HC otic suspension—marking the company's fourth CGT launch in three years.
September 2025
September 2025 - Professional Accolades: * Bronze Stevie® Award: Named Employer of the Year (Pharmaceuticals).
HDA Recognition: Honored by the Healthcare Distribution Alliance for excellent service to distributor partners.
February 2025
February 2025 - Operational Excellence: Appointed Vincent Colicchio as Senior Vice President of Operations to lead global manufacturing and supply chain strategy.
July 2024
Acceleration & Innovation
July 2024 - Capital Partnership: Hamilton Lane joined Avista Capital Partners as a significant equity investor in Cosette.
Global Brand Acquisition: Completed the acquisition of Ambien® and Ambien CR® from Sanofi US.
February 2024
February 2024 - Regulatory Milestone: FDA approval and launch of the first generic version of RECTIV® (nitroglycerin ointment 0.4%) with 180-day CGT exclusivity.
Late 2023
Late 2023 - Strategic Acquisitions & Partnerships: * Acquired Vyleesi® (bremelanotide) from Palatin Technologies, the only FDA-approved as-needed treatment for HSDD.
- Partnered with Mark Cuban Cost Plus Drug Company to provide affordable access to CLOMID®.
June 2023
June 2023 - Leadership Recognition: * CEO Apurva Saraf named EY Entrepreneur Of The Year® 2023 New Jersey.
- Apurva Saraf honored as "CEO of the Year" by Avista Capital Partners.
June 2023 - Women’s Health Expansion: Acquired Intrarosa® from Endoceutics, Inc., adding a patent-protected product to its women’s health portfolio.
January 2022
The Transformation
January 2022 - Strategic Portfolio Growth: Carve-out acquisition of eight branded commercial products from Daiichi Sankyo, including cardiovascular and antihypertensive therapies.
Q4 2021
Q4 2021 - Cosette acquired 8 brand products from Daiichi Sankyo
Q3 2020
Q3 2020 - Appointed Apurva Saraf as the new CEO.
November 2019
November 2019 - Manufacturing Integration: Cosette acquired the G&W finished dosage plant in Lincolnton, NC, establishing its internal manufacturing and CDMO (Contract Development and Manufacturing) vertical.
December 2018
December 2018 - The Birth of Cosette: Formed via the acquisition of G&W Laboratories’ topicals and dermatology portfolio by Avista Capital Partners.
1945
Heritage & Foundation
1945 - The company expanded into topicals, including creams, ointments, and gels.
1919
1919 - The company pioneered innovative suppository dosage forms.
